openPR Logo
Press release

Respiratory Inhalers Market, By Devices, Technology, Therapeutic Application, and Geography - Insights, Opportunity Analysis, and Industry Forecast till 2024

10-14-2017 01:32 PM CET | Health & Medicine

Press release from: Respiratory Inhalers Market

Respiratory Inhalers Market, By Devices, Technology,

Respiratory Inhalers – Getting the Wind Back in Your Lungs

Respiratory diseases such as bronchitis, asthma, allergic rhinitis, pneumonia and sinusitis can significantly curtail the physical activities of the individual. The symptoms associated with both mild and severe manifestations of these respiratory conditions include coughing, wheezing, chest pain, respiratory distress, shortness of breath, congestion, and even death in severe cases. These conditions lead to substantial morbidity and causes large cost of burden to the society. Increasing air pollution can severely affect respiratory health of children as well as adults.

Request to download and view Sample Report:

Various studies conducted have shown the ill effects of air pollution that can exacerbate existing respiratory conditions such as asthma, COPD, and upper airway allergies. According to the Forum of International Respiratory Societies, in 2013, young children and infants were especially susceptible to respiratory diseases. Around 9.0 million children under the age of 5 years die per year and the common thing in them is the presence of lung diseases. Increase in evidences through such studies suggests that the exposure to certain type of air pollutants contributes to the onset of asthma. However, studies related to the exacerbation of pre-acquired and existing asthma are more prevalent as they provide favorable conditions to study.

The global respiratory inhalers market was valued at US$ 25,846.7 million in 2015 and is expected to witness a robust CAGR of 4.2% during the forecast period (2016 – 2024).

Generic Respiratory Inhalers are expected to be Major Revenue Generators for Market Players

According to Next Breath, LLC, in 2013, in the U.S for asthma/COPD there were no generic inhalers available, which includes both categories of standard asthma treatment such as controller medications for long-term prevention and rescue medication for quick relief. The above inhalers medicine average cost ranges between US$ 35 and US$ 300, rendering the treatment expensive for both consumers that are insured as well as uninsured. Furthermore, there are various many pressurized metered dose inhalers (pMDIs) that are approaching towards the patent expiration, and due to the lack of a document from the U.S. Food and Drug Administration (FDA) for guidance, generic companies are reluctant to spend in new product development, which finally might not be acceptable to the agency. According to Forum of International Respiratory Societies, in 2013, it has been estimated that around 235 million people suffered from asthma and more than 200 million people were affected from chronic obstructive pulmonary disease (COPD), and around 65 million endure mild-to-severe COPD. Also, around 2 billion people were exposed to the toxic effects of biomass fuel consumption and air pollution and by tobacco smoke.

Request a Customization:

Growth in respiratory inhalers market on the backdrop of product launches and Technological Advancements

In 2017, Cipla launched Synchrobreathe, a revolutionary inhaler that will bring great relief to millions of South Africans with obstructive airway diseases (OAD) such as asthma
In 2010, around 115,000 patients were hospitalized due to sever chronic obstructive pulmonary disease, which cost the NHS around US$ 367.85 Mn and is expected to increase over the forecast period. Sandoz launched an innovative respiratory inhaler AirFluSal Forspiro in the UK to capitalize on the highly lucrative market in the region.
Increasing number of research collaborations is expected to improve the time-to-market of highly effective and advanced products

Browse Research Report At:

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702
Visit Coherent Market Insights Blog @
Connect with us on LinkedIn @

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Respiratory Inhalers Market, By Devices, Technology, Therapeutic Application, and Geography - Insights, Opportunity Analysis, and Industry Forecast till 2024 here

News-ID: 773710 • Views: 339

More Releases from Respiratory Inhalers Market

Respiratory Inhalers Market - Global Industry Analysis 2025
Chronic respiratory diseases are the group of chronic diseases which affect airways, lungs and the other parts of respiratory system. Chronic respiratory disease include asthma and respiratory allergies, Chronic Obstructive Pulmonary Disease (COPD), Occupational Lung Diseases, Sleep Apnoea Syndrome and Pulmonary Hypertension. However 70% chronic respiratory disease are asthma and chronic obstructive pulmonary disease. In 2012, globally, 1 billion people are affected with chronic respiratory disease and account for 7%

More Releases for COPD

COPD Therapeutics Global Market Research Report 2019
COPD Therapeutics Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications and market
COPD: Disease Insights and Market Forecasts to 2024 by Pharmascroll
“COPD: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of COPD disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for COPD, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024. Geographies covered: US Germany France Italy Spain UK Japan Australia Canada Drugs
SMi's Asthma & COPD conference next week in London
SMi Group reports: Limited availability on Managers Special Discount Last call [Managers Special offer - £500 savings] on SMi's Asthma & COPD conference, taking place on 11 – 12 April in London - to Directors, Principle scientists, Senior scientists, Associate directors, Managing directors, Medical directors, Pharmaceutical experts, Group leaders, Inhalation toxicologists of: clinical pharmacology; respiratory medicine/ science; respiratory immunology; pulmonary specialty; respiratory physiology. Organisers are glad to welcome Richard Marsden, Chief Executive
Global COPD and Asthma Devices Market Size
According to a new report, Global COPD and Asthma Devices Market, published by KBV Research, The Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 – 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would
COPD Drug Market Opportunity & Clinical Pipeline Analysis
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the
Global COPD inhalers Industry:-Forecast 2022
Chronic Obstructive Pulmonary Disease (COPD) is a wide term used for progressive lung diseases which includes chronic bronchitis, emphysema, refractory asthma, and some forms of bronchiectasis. The symptoms of COPD includes recurrent coughing with or without sputum, difficulty in breathing, wheezing and tightness in the chest due to the blockage of lungs’ airways. More than 70 million people in the world are suffering from COPD as of 2015, majority of